OASM - Oasmia Pharmaceutical AB (publ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4700
0.0000 (0.00%)
At close: 3:08PM EDT
Stock chart is not supported by your current browser
Previous Close1.4700
Open1.4900
Bid1.4000 x 1200
Ask2.3200 x 800
Day's Range1.4700 - 1.5000
52 Week Range0.8000 - 3.1650
Volume1,716
Avg. Volume8,812
Market Cap104.52M
Beta0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.2400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

    FOURTH QUARTER February 1, 2018– April 30, 2018. Consolidated net sales amounted to TSEK 843 compared to TSEK 44 in the fourth quarter the previous year Operating loss was TSEK 28,017 compared to TSEK ...

  • GlobeNewswirelast month

    Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

    During Monday Oasmia Pharmaceutical AB presented the follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer. Uppsala, Sweden, June 5, 2018 - The 2018 ASCO Annual Meeting is ongoing in Chicago with 33,000 international attendees interested in clinical oncology. Oasmia presented the follow-up results from the study including 789 patients with platinum-sensitive recurrent ovarian cancer during Monday.

  • GlobeNewswire2 months ago

    Nexttobe Extends Loan to Oasmia Pharmaceutical

    Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The current loan from Nexttobe ...

  • GlobeNewswire2 months ago

    Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

    Oasmia Pharmaceutical AB (OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets into its wholly owned, US-based subsidiary, AdvaVet, Inc. With this move completed, AdvaVet, Inc. can begin to unlock value for Oasmia shareholders through the development and commercialization of two new chemotherapy drugs that specifically target companion animals. AdvaVet has started to build infrastructure in the US and has recently hired an experienced CEO and CFO from the veterinary industry, as well as a predominately US-based Board of Directors, who possess extensive commercial and financial experience, the company will gradually build out its commercial infrastructure in parallel with completing the clinical development of Doxophos Vet and Paccal Vet.

  • GlobeNewswire2 months ago

    Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

    Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago. Uppsala, Sweden, May 17, 2018 - ASCO (American Society of Clinical Oncology) is an organization for clinical oncologists and provides recommendations for clinical practices and publishes the scientific journal Journal of Clinical Oncology among other things. The 2018 ASCO Annual Meeting will be held in Chicago between 1-5, June and about 32 000 international attendees with interests in clinical oncology are expected to attend.

  • GlobeNewswire2 months ago

    Notification from Oasmia Pharmaceutical

    Oasmia Pharmaceutical AB hereby notify that the Company, Arwidsro Investment and MGC Capital have agreed to extend the payment of the loan, which was communicated January 2 nd until September 30 th. The ...

  • GlobeNewswire2 months ago

    Notification from Oasmia Pharmaceutical AB

    Oasmia Pharmaceutical AB hereby issues a notification that EMA has given 60 days response time instead of 30 days as previously communicated and requested by the company. Oasmia will respond to the list ...

  • GlobeNewswire2 months ago

    Notification from Oasmia Pharmaceutical AB

    Oasmia Pharmaceutical AB hereby issues a notification that the Company has submitted a Form F-3 to SEC which is a required document in case the Company would need to do a financial transaction in the US during the coming three years. SEC has 30 days to respond to the document before it goes live.

  • GlobeNewswire3 months ago

    Notification from Oasmia Pharmaceutical AB

    Uppsala, Sweden, April 24, 2018– Oasmia Pharmaceutical AB hereby issues a notification regarding the issuance of the agenda for EMA’ s CHMP meeting April 23– 26. Instead of the announced oral explanation, ...

  • GlobeNewswire3 months ago

    Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

    Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an interest rate of 8 per cent per year directed to and placed with a limited group of investors and paid in cash (the “Private Placement”). The convertible instrument issue is expected to provide the Company with SEK 26,000,000 before transaction related costs.

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
    Capital Cube10 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Ohr Pharmaceutical, Inc. (OMED-US, OMER-US and OHRP-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)